RhoA activation and actin reorganization involved in endothelial CAM-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1

Blood
Carmen GarnachoSilvia Muro

Abstract

Platelet-endothelial cell adhesion molecule-1 (PECAM-1), a transmembrane glycoprotein involved in leukocyte transmigration, represents a good target for endothelial drug delivery (eg, using antibody-directed nanocarriers, anti-PECAM/NCs). Although endothelial cells do not internalize PECAM antibodies, PECAM-1 engagement by multivalent anti-PECAM conjugates and nanocarriers causes endocytosis via a nonclassic CAM-mediated pathway. We found that endothelial uptake of multivalent anti-PECAM complexes is associated with PECAM-1 phosphorylation. Using model REN cells expressing a series of PECAM-1 deletion and point mutants, we found that the PECAM-1 cytoplasmic domain and, more precisely, PECAM-1 tyrosine 686, is critical in mediating RhoA activation and recruitment of EGFP-RhoA to anti-PECAM/NC binding sites at the plasmalemma, actin polymerization into phalloidin-positive stress fibers, and finally CAM endocytosis of anti-PECAM/NCs. Endothelial targeting and endocytosis of anti-PECAM/NCs were markedly efficient and did not compromise endothelial barrier function in vitro (determined by immunostaining of VE-cadherin and (125)I-albumin transport across endothelial monolayers) or in vivo (determined by electron microscopy imaging of...Continue Reading

References

Sep 5, 1995·Biochemical and Biophysical Research Communications·N HaradaK Fujiwara
Aug 1, 1993·The Journal of Experimental Medicine·W A MullerD M Phillips
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·T T LuJ A Madri
Jan 1, 1997·The Journal of Clinical Investigation·P J Newman
Jul 6, 2000·The American Journal of Pathology·S MahootiJ A Madri
Aug 25, 2000·American Journal of Physiology. Lung Cellular and Molecular Physiology·T StevensA B Malik
Dec 29, 2000·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·A Hall, C D Nobes
Sep 7, 2001·Current Opinion in Cell Biology·R A Worthylake, K Burridge
Feb 6, 2002·The Journal of Clinical Investigation·Donnasue GraesserJoseph A Madri
Sep 18, 2002·Immunological Reviews·Francis W LuscinskasSunil K Shaw
Dec 13, 2002·Nature·Sandrine Etienne-Manneville, Alan Hall
Mar 11, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·John GreenwoodPeter Adamson
Mar 18, 2003·Journal of Cell Science·Silvia MuroMichael Koval
Apr 12, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Peter J Newman, Debra K Newman
Jul 10, 2003·American Journal of Physiology. Lung Cellular and Molecular Physiology·Melpo Christofidou-SolomidouVladimir R Muzykantov
Jul 25, 2003·American Journal of Physiology. Cell Physiology·Silvia MuroMichael Koval
Aug 2, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Dita GratzingerJoseph A Madri
Jun 18, 2004·American Journal of Physiology. Cell Physiology·Christopher D O'BrienHorace M DeLisser
Jul 14, 2004·Biochemical and Biophysical Research Communications·David A KaufmanPeter F Davies
Aug 21, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Matthias MaasPeter J Newman
Aug 24, 2004·Current Vascular Pharmacology·Silvia MuroVladimir Muzykantov
Jan 6, 2005·The American Journal of Pathology·Michael CarrithersJoseph A Madri
Oct 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·Roland KaunasShu Chien
Nov 22, 2005·Expert Opinion on Drug Delivery·Vladimir R Muzykantov
Nov 22, 2005·American Journal of Physiology. Lung Cellular and Molecular Physiology·Silvia MuroMichael Koval

❮ Previous
Next ❯

Citations

Aug 16, 2011·ACS Nano·Vladimir V ShuvaevVladimir R Muzykantov
Jun 19, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Silvia MuroVladimir R Muzykantov
Aug 2, 2012·Journal of Nanobiotechnology·Tore Geir IversenKirsten Sandvig
Aug 19, 2009·Proceedings of the American Thoracic Society·Kerri A Massey, Jan E Schnitzer
Sep 29, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tridib BhowmickSilvia Muro
May 13, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jingyan HanVladimir R Muzykantov
Nov 4, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Vladimir V ShuvaevVladimir R Muzykantov
Jan 30, 2010·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Silvia Muro
May 16, 2015·Clinical Science·Sunyoung ParkNader Sheibani
Apr 5, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Vladimir V Shuvaev, Vladimir R Muzykantov
Jul 29, 2008·Microvascular Research·Natalia V Bogatcheva, Alexander D Verin
May 24, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Vladimir V ShuvaevVladimir R Muzykantov
Dec 10, 2013·American Journal of Physiology. Lung Cellular and Molecular Physiology·Rebecca L OrndorffShampa Chatterjee
Apr 4, 2021·Biomedicines·Thijs J SluiterMargreet R de Vries
May 16, 2017·Advanced Drug Delivery Reviews·Melani Solomon, Silvia Muro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cavernous Hemangioma

Cavernous hemangioma is a blood vessel defect or benign tumor that leads to leakage of blood to the surrounding tissues. This can occur in several organs including the brain, which can lead to seizures. Discover the latest research on cavernous hemangiomas here.

Related Papers

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
Arnaud ScherpereelVladimir R Muzykantov
Journal of Controlled Release : Official Journal of the Controlled Release Society
Vladimir V ShuvaevVladimir R Muzykantov
© 2021 Meta ULC. All rights reserved